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    Ninety－three patients with prostatic carcinoma were treated at Nara Medical University between
1969， April and 1980， ］N4arch． The average age of patients was 70．6 ’凾?≠窒?old and the age range was
between 50 and 87． Ninety－one patients of whom had histologically proved adenocarcinoma， and
two patients had proved transitional cell carcinoma of the prostate，
    Initial clinical stage was as follows： stage A 7 cases （7．50／，）， stage B 6 cases （6．5C／，）， stage C 39
cases （41．9C／．） and stage D 41 cases （44．10／，）． Histological grade was determined as follows： well
differentiated type 20 cases （21．50／，）， moderately differentiated type 53 cases （57．09！，）， poorly differ－
entiated type 9 cases （9．70／．） and unidentified 9 cases （9．70／，）．
   Of ninety－three patients， 66． were treated with anti－andregen therapy， and 21 were treated with
radiotherapy andfor chemotherapy because they had no response to initial hormonal manipulation，
and remaining 6 cases underwent radical prostatectorny with adjuvant anti－androgen therapy．
   Relapse was seen in 20 patients： 15 were in the group of anti－androgen therapy， 4 were in the
group of radiotherapy and／or chemotherapy following anti－androgen therapy and one was in the
greup of radical prostatectomy． The interval to relapse was 2．2 years on the average （range： 8 months
to 6 years）．
   Five years actuarial survival rates were 37．70／， in the group of anti－androgen therapyi and 61．90／．
in the group of radiotherapy and／or chemotherapy， and the significant difference between these two
groups was not seen．
   The 5 patients diagnosed as stage D adenocarcinoma of the prostate， 4 of whom had multiple
bone metastasis and 2 had liver metastasis in addition to bone metastasis， showed favorable response















































Table 1． 且istological classification and clinical stage of prostatic carcinoma at the且rst manifestation
in the Urological Clinic of Nara Medical Univ． （1969， April一一1980， March）
Clin童ca監StageHistological Classification
A B c D
Total
Adenocarcinoma
 Well differentiated type
 Moderately differentiated type





















Tota1 7 6 39 41 93
Table 2． lnitial treatrnent of prostatic carcinoma
Treatment Clinical Stage





For hermonally unresponsive cases
 Radiotherapy






















   Total 7Cl） 6（6）
＊ ：including a case of trans itional ceil careinoma
＊ ＊ ： a case treated with antiandrogen therapy after chemotherapy
（ ） ：patients with bilateral orchiectomy
39侶9） 41 ｛40） 93圃
    塩見・ほか：ホルモン非依存性前立腺癌
Table 3． Evaluation of Cis－DDP for prostatic carcinoma
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＊ ： relapsing case in the maintenance antiandregen therapy
Table 4．Clinical course of relapsing cases in the maintenanc anti－androgen therapy
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  1969 ，70  ，71 ，72  ’73 ’74  ，75 ’76 ，77  ’7ぎ ’79  ，80
         Year
  口・・…一and・・gen・h・・apy
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  ％ ：radietherapy
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   ＊ ： including two cases with transitional
     cell carcinoma
Fig． 1． Yearly distribution of initial treatment




Subjective response of anti－androgen therapy， chemotherapy， immuno－
chemotherapy and radiotherapy for prostatic carcinoma























1／1 ’i1 oo o／e）
1／1 （100e／e）
2 ／2 （1 oo o／e）
Table 6．Objective response of anti－androgen therapy， chemotherapy and radiotherapy
for primary狐d metastat量。 lesions of prostatic adenocarcinoma
Regression

























Tota1 85十6’ 2 62〈6） 12ua 3｛3） 11（13）
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Fig． 2． Actuarial survival rate according to clinical stage
（o／o）
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